Onswik, Lilly's once-weekly basal insulin, gains FDA approval. #DrugApproval https://www.empr.com/news/fda-approves-onswik-insulin-efsitora-type-2-diabetes/
@medicalprofref.bsky.social
@medicalprofref.bsky.socialOnswik, Lilly's once-weekly basal insulin, gains FDA approval. #DrugApproval https://www.empr.com/news/fda-approves-onswik-insulin-efsitora-type-2-diabetes/
@dengyuemedicine.bsky.socialSame drug. New shape. Big difference for patients.
China's NMPA just approved a tablet version of selpercatinib (Retevmo) — the world's first highly selective RET inhibitor with CNS activity — expanding on its 2022 capsule approval. 🧪
@gmj-georgia.bsky.socialBreaking: Semaglutide (Wegovy) becomes the first GLP-1 receptor agonist approved to treat metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-a… #Drugapproval #Fibrosis #GLP1agonists #Hepatology #Liverdisease #Drugapproval #Fibrosis #GLP1agonists #Hepatology #Liverdisease …
@gmj-georgia.bsky.socialBreaking: Semaglutide (Wegovy) becomes the first GLP-1 receptor agonist approved to treat metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-a… #Drugapproval #Fibrosis #GLP1agonists #Hepatology #Liverdisease #Drugapproval #Fibrosis #GLP1agonists #Hepatology #Liverdisease …